Pharmaceutical company Eli Lilly is warning that two of its insulin offerings for diabetic patients will be temporarily out of stock through the beginning of April. 

The drug maker released a statement on April 2, detailing how its 10 milliliter vials of Humalog and Insulin Lispro Injection won't be widely available at some pharmacies and wholesalers. Eli Lilly also said that all of its other insulin products — including Humalog and Insulin Lispro injection in prefilled pens — are still available across the U.S. 

"We recognize that any supply challenge may cause a disruption in people’s treatment regimens, and we are moving with urgency to address it," the company said in a written release. "Anyone experiencing difficulty in getting their prescription filled should contact their healthcare provider to discuss switching to the same insulin in a prefilled pen or other insulin treatment options."

As for what led to the shortage, Eli Lilly told CNN that it was the fault of the "dynamic nature of insulin supply and demand, coupled with a brief delay in manufacturing," which led to a "temporary supply constraint."